CH638099A5 - Composition for the treatment of dermatoses characterised by hyperpigmentation - Google Patents
Composition for the treatment of dermatoses characterised by hyperpigmentation Download PDFInfo
- Publication number
- CH638099A5 CH638099A5 CH690677A CH690677A CH638099A5 CH 638099 A5 CH638099 A5 CH 638099A5 CH 690677 A CH690677 A CH 690677A CH 690677 A CH690677 A CH 690677A CH 638099 A5 CH638099 A5 CH 638099A5
- Authority
- CH
- Switzerland
- Prior art keywords
- bromine
- preparation
- process according
- active component
- acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 17
- 208000017520 skin disease Diseases 0.000 title claims description 12
- 208000000069 hyperpigmentation Diseases 0.000 title claims description 3
- 230000003810 hyperpigmentation Effects 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 claims description 10
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 5
- 230000000711 cancerogenic effect Effects 0.000 claims description 5
- 231100000315 carcinogenic Toxicity 0.000 claims description 5
- 235000019441 ethanol Nutrition 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- 238000007127 saponification reaction Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- PVFOHMXILQEIHX-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-bromophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Br PVFOHMXILQEIHX-UHFFFAOYSA-N 0.000 claims 2
- 150000001535 azelaic acid derivatives Chemical class 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 6
- 150000001991 dicarboxylic acids Chemical class 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 206010048768 Dermatosis Diseases 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 241000555688 Malassezia furfur Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- LWBHHRRTOZQPDM-UHFFFAOYSA-N undecanedioic acid Chemical compound OC(=O)CCCCCCCCCC(O)=O LWBHHRRTOZQPDM-UHFFFAOYSA-N 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000029966 Hutchinson Melanotic Freckle Diseases 0.000 description 1
- 206010024218 Lentigo maligna Diseases 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010057041 Poikiloderma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001536 azelaic acids Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000003047 pimelic acids Chemical class 0.000 description 1
- 201000000508 pityriasis versicolor Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- -1 sebacic Chemical compound 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DXNCZXXFRKPEPY-UHFFFAOYSA-N tridecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCC(O)=O DXNCZXXFRKPEPY-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT22617/77A IT1075741B (it) | 1977-04-19 | 1977-04-19 | Composizione per il trattamento di dermatosi iperpigmentarie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH638099A5 true CH638099A5 (en) | 1983-09-15 |
Family
ID=11198481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH690677A CH638099A5 (en) | 1977-04-19 | 1978-01-01 | Composition for the treatment of dermatoses characterised by hyperpigmentation |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS53130433A (enrdf_load_stackoverflow) |
| AU (1) | AU524602B2 (enrdf_load_stackoverflow) |
| BE (1) | BE866151A (enrdf_load_stackoverflow) |
| CA (1) | CA1137873A (enrdf_load_stackoverflow) |
| CH (1) | CH638099A5 (enrdf_load_stackoverflow) |
| DE (1) | DE2817133A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1603563A (enrdf_load_stackoverflow) |
| IT (1) | IT1075741B (enrdf_load_stackoverflow) |
| ZA (1) | ZA782125B (enrdf_load_stackoverflow) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8302683D0 (en) * | 1983-02-01 | 1983-03-02 | Unilever Plc | Skin treatment composition |
| JPS61130205A (ja) * | 1984-11-30 | 1986-06-18 | Sunstar Inc | アスコルビン酸を安定に配合した水系組成物 |
| US4713394A (en) * | 1986-01-17 | 1987-12-15 | Thornfeldt Carl R | Treatment of nonacne inflammatory and infectious dermatoses and hair loss |
| JP2565513B2 (ja) * | 1987-09-25 | 1996-12-18 | 三省製薬株式会社 | メラニン生成抑制外用薬剤 |
| EP0345082A3 (en) * | 1988-06-02 | 1990-04-04 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Enzyme formation suppressing agent |
| EP0345081A3 (en) * | 1988-06-02 | 1990-03-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Enzyme formation suppressing agent |
| DE10039783A1 (de) * | 2000-08-16 | 2002-02-28 | Cognis Deutschland Gmbh | Kosmetische Zubereitungen |
| ITMI20041567A1 (it) * | 2004-07-30 | 2004-10-30 | Maycos Italiana Di Comini Miro | "derivati n-acilati di acidi bicarbossilici con amminoacidi e con idrolizzati proteici vegetali e loro applicazione in prodotti cosmetici, dermofarmaceutici e farmaceutici" |
| DE102006004804A1 (de) | 2006-01-23 | 2007-07-26 | Intendis Gmbh | Verwendung von Alkandicarbonsäuren und Retinoiden zur Behandlung entzündlicher Hauterkrankungen |
| IL181577A0 (en) * | 2007-02-26 | 2007-07-04 | Jacob Bar Tana | Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders |
| DE102010021671A1 (de) | 2010-05-27 | 2011-12-01 | Intendis Gmbh | Azelainsäurehaltige Formulierung mit Pigmentzusatz |
| JP2013170158A (ja) * | 2012-02-22 | 2013-09-02 | Kao Corp | 経口紫外線抵抗性向上剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2878237A (en) * | 1955-06-15 | 1959-03-17 | American Cyanamid Co | Mercapto dibasic acids as regulators for the polymerization of acrylic acids, amidesand salts |
-
1977
- 1977-04-19 IT IT22617/77A patent/IT1075741B/it active
-
1978
- 1978-01-01 CH CH690677A patent/CH638099A5/it not_active IP Right Cessation
- 1978-04-12 AU AU35027/78A patent/AU524602B2/en not_active Expired
- 1978-04-13 CA CA000301093A patent/CA1137873A/en not_active Expired
- 1978-04-13 ZA ZA00782125A patent/ZA782125B/xx unknown
- 1978-04-14 JP JP4340978A patent/JPS53130433A/ja active Granted
- 1978-04-18 GB GB15187/78A patent/GB1603563A/en not_active Expired
- 1978-04-19 BE BE186928A patent/BE866151A/xx not_active IP Right Cessation
- 1978-04-19 DE DE19782817133 patent/DE2817133A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| ZA782125B (en) | 1979-03-28 |
| JPS631287B2 (enrdf_load_stackoverflow) | 1988-01-12 |
| DE2817133A1 (de) | 1978-11-02 |
| IT1075741B (it) | 1985-04-22 |
| JPS53130433A (en) | 1978-11-14 |
| BE866151A (fr) | 1978-10-19 |
| CA1137873A (en) | 1982-12-21 |
| DE2817133C2 (enrdf_load_stackoverflow) | 1988-08-11 |
| AU524602B2 (en) | 1982-09-23 |
| AU3502778A (en) | 1979-10-18 |
| GB1603563A (en) | 1981-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4386104A (en) | Process for the treatment of acne | |
| US4292326A (en) | Process for treatment of hyperpigmentary dermatoses | |
| CH638099A5 (en) | Composition for the treatment of dermatoses characterised by hyperpigmentation | |
| EP0366713B1 (en) | Esters of 13-trans-retinoic acid | |
| EP0920312B1 (en) | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents | |
| DE69609868T2 (de) | Neue steroidester zur behandlung von hauterkrankungen | |
| JP6219410B2 (ja) | レスベラトロール誘導体の皮膚美白用途 | |
| JPH0848620A (ja) | スキンライトニング組成物 | |
| US6825226B2 (en) | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias | |
| EP0097059A2 (en) | Skin treatment compositions | |
| CA1297030C (en) | Treatment of psoriasis, ichthyosis, and acne with manoalide | |
| EP0584191B1 (fr) | Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique | |
| CH667868A5 (fr) | Derives du benzonorbornene, leurs procedes de preparation et compositions medicamenteuse et cosmetique les contenant. | |
| JP2009529572A (ja) | １８β−グリチルレチン酸の誘導体 | |
| DE69801878T2 (de) | Verwendung von Oxamatderivaten als Depigmentierungsmittel | |
| JPS62215581A (ja) | フラボンカルボン酸誘導体 | |
| US5443844A (en) | Linoleic acid preparations for topical treatment of acne vulgaris | |
| JPS6466119A (en) | Free fatty acid for treating diabetes | |
| Sorg et al. | Preparation of retinoic acid esters of phorbol derivatives. | |
| JP2020513417A (ja) | ビタミンａ５経路のレチノイド類を提供するための前駆体化合物及びその使用 | |
| US20180116933A1 (en) | Anti-oxidative or anti-aging composition containing 5-adamantan-1-yl-n-(2,4-dihydroxybenzyl)-2,4-dimethoxybenzamide | |
| EP2509944B1 (en) | Novel peroxide derivatives, their process of preparation and their use in human medicine and in cosmetics for the treatment or prevention of acne | |
| FI66834C (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva omega-dialkylalkansyrederivat | |
| JP6696060B1 (ja) | 新規ビタミンａ誘導体およびその製造方法 | |
| CN119080586A (zh) | 1,3-双苄基苯酚类化合物、制备方法及其在美白抗衰化妆品中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |